ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2021
Incidence, Risk Factors, and Outcomes of Pouchitis and Pouch-Related Complications in Patients With Ulcerative Colitis.
Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 58 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Rifaximin for the Secondary Prevention of Recurrent Pouchitis
Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch
Who cites it
58 citing papers in PubMed, 4 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Risk factors for chronic pouchitis in patients with ulcerative colitis following ileal pouch-anal anastomosis: a meta-analysis.Frontiers in medicine · 2026Pooled it
- Medical Therapies for Prevention and Treatment of Inflammatory Pouch Disorders-A Systematic Review and Meta-Analysis.The American journal of gastroenterology · 2025Pooled it
- Complications and failure after Kock continent ileostomy: A systematic review and meta-analysis.Techniques in coloproctology · 2024Pooled it
- AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders.Gastroenterology · 2024Guideline
- From gut dysbiosis to eubiosis: understanding microbiome recovery as an ecological process.Gut microbes · 2026Review
- Impact of Diet and Body Mass Index on the Development of Pouchitis in the First Year After Ileal Pouch-Anal Anastomosis.Digestive diseases and sciences · 2026Article
- The Gut Microbiome in Pouchitis: A Narrative Review of Pathogenesis and Therapeutic Modulation.Nutrients · 2026Review
- Abnormal MUC1 Expression as a Biomarker for Pouchitis.Digestive diseases and sciences · 2026Article
- Endoscopic Management of Pouch Volvulus as a Complication of Ileal Pouch Anal Anastomosis in Patients With Ulcerative Colitis.ACG case reports journal · 2026Article
- Long-term Outcomes Following Colectomy and Liver Transplantation for Inflammatory Bowel Disease With Primary Sclerosing Cholangitis.Annals of surgery · 2026Article
- The efficacy and safety of hyoscyamine, dicyclomine, and desipramine in the treatment of irritable pouch syndrome-a retrospective cohort study.Crohn's & colitis 360 · 2026Article
- Anti-integrin αvβ6 autoantibody in patients with ulcerative colitis after proctocolectomy: a cross-sectional study in Japan.Intestinal research · 2026Article
- Sequence Analysis Identifies Clusters of Antibiotic Use After the First Episode of Pouchitis in a Population-Based Study That May Represent High-Risk Phenotypes.The American journal of gastroenterology · 2026Article
- Optimal Antibiotic Selection for the Treatment of Pouchitis After Ileal Pouch-Anal Anastomosis.Journal of inflammation research · 2026Review
- Cost Effectiveness of the 8-Strain Probiotic in Primary and Secondary Prophylaxis of Pouchitis.Gastro hep advances · 2026Article
- Cellular and molecular mechanisms in the pathogenesis of pouchitis: more than just the microbiota.Gut · 2025Review
- Emerging concepts and shifting paradigms for understanding the microbial basis of inflammatory bowel diseases.The Journal of clinical investigation · 2025Review
- Managing Pouchitis: Where do Antibiotics End, and Advanced Therapies Begin?Current gastroenterology reports · 2025Review
- Optimal Approaches to Treating and Preventing Acute and Chronic Pouchitis by Altering Microbial Profiles.Gastroenterology clinics of North America · 2025Review
- Anti-tumor Necrosis Factor Drug Concentration Is Not Associated with Disease Outcomes in Pouchitis: A Retrospective, International Study.Digestive diseases and sciences · 2025Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND &
aimsAcute pouchitis is the most common non-surgical complication after restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC). We used validated case-finding definitions for pouchitis to search administrative claims data and determine the incidence of pouchitis in the first 2 years after IPAA.
methodsWe identified all patients who underwent proctocolectomy with IPAA for UC in the IQVIA Legacy PharMetrics Adjudicated Claims Database, from January 1, 2007 through June 1, 2016. The primary outcome was the development of pouchitis within 2 years after IPAA. Secondary outcomes included isolated acute vs recurrent pouchitis, immunosuppressive therapy, further surgery, and admission to the hospital.
resultsAmong 594 patients, the cumulative incidence of pouchitis within 2 years of IPAA was 48% (95% CI, 44%-52%). The cumulative incidence of isolated acute pouchitis was 29% (95% CI, 26%-33%). Compared to patients with isolated acute pouchitis, patients who received a diagnosis of recurrent pouchitis (cumulative incidence, 19%: 95% CI, 16%-22%) demonstrated increased outpatient visits, emergency department visits, and inpatient admissions (all P < .001). Patients who developed pouchitis were more likely to have a history of primary sclerosing cholangitis (adjusted odds ratio [aOR], 3.94; 95% CI, 1.05-14.8) and anti-tumor necrosis factor alpha therapy prior to colectomy (aOR 1.63; 95% CI, 1.09-2.45). Among patients with pouchitis, the cumulative frequency of new immunosuppressive therapy was 40% (95% CI, 35%-46%) and the cumulative incidence of pouch excision was 1.0% (95% CI, 0.4%-3.0%). The cumulative incidence of a new diagnosis of Crohn's disease after IPAA for UC was 9.0% (95% CI, 7.2%-11%).
conclusionsIn a geographically diverse population, 48% of patients with UC developed pouchitis within the first 2 years after IPAA. Patients with pouchitis had greater use of healthcare resources, indicating a significant burden of disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.